Endothelial dysfunction symbolizes several pathological conditions, including altered anticoagulant and anti-inflammatory properties of the endothelium, impaired modulation of vascular growth, and dysregulation of vascular remodeling. Nevertheless, this term has been used commonly to refer to an impairment of endothelium-dependent vasorelaxation caused by a loss of nitric oxide bioactivity. The clinical and scientific relevance of nitric oxide synthesis and bioavailability in endothelial dysfunction is based on the fact that it is a common factor in the pathogenesis of cardiovascular diseases. These alterations have been demonstrated in both animal models and humans, in the scope of dangerous pathological conditions such as cigarette smoking, hypertension, hypercholesterolemia, aging, diabetes, and heart failure. A decline in nitric oxide bioavailability may be caused by decreased expression of the endothelial nitric oxide synthase, a reduction of substrate or cofactors for this enzyme, alterations of cellular signaling, enzyme inhibition by asymmetric dimethyl arginine, and, finally, accelerated nitric oxide degradation by reactive oxygen species. The knowledge of the processes related to these alterations becomes of remarkable importance for understanding the generation of innovative and effective therapeutic strategies for cardiovascular diseases.
INTRODUCTION
Vascular endothelial cells constitute a structurally simple but functionally complex system that regulates a number of processes such as hemostasis, fibrinolysis, inflammation, blood pressure, lipoprotein metabolism, and angiogenesis, and in this way they play an essential role in the homeostasis of the vascular system. Alterations in one or more of these physiological phenomena are known as endothelial dysfunction 1 ( Figure 1 ). Even though the association between several risk factors and cardiovascular diseases is well documented, it is often observed that some individuals who present some of these factors do not develop cardiovascular diseases, which suggests there is an ''activating connector'' that once affected significantly joins risk factors with cardiovascular pathologies through some anomalous processes. Because of their strategic location and biological properties, vascular endothelial cells constitute this ''hot key'' in the chain of events that end in vascular system dysfunction. 2 Endothelium-dependent relaxation alteration by a decrease in both synthesis and nitric oxide (NO) bioavailability constitute the earlier and most important phenomenon in endothelial dysfunction. 3 NO carries out important functions related to vascular system homeostasis, such as vessel tone regulation, inhibition of platelet aggregation, leukocyte adhesion and transmigration inhibition, as well as proliferation and migration of smooth-muscle cells. Hence, a decrease in this molecule's activity constitutes a major element in the pathophysiological processes that ends in cardiovascular atherosclerotic diseases. 4 However, these transformations, besides being complex and diverse, have not been completely clarified. 5 
ENDOTHELIAL NITRIC OXIDE SYNTHASE (eNOS) BIOLOGY
NO is a nitrogen-centered free radical produced exclusively by nitric oxide synthase (NOS) action. Three isoforms of this enzyme have been described that are highly homologous in their primary structure. Inducible NOS (iNOS) is expressed in the phagocytic cells by pro-inflammatory stimuli such as cytokines. The two other isoforms are constitutively expressed in nervous tissue (nNOS) and the endothelial cells (eNOS). 6 eNOS synthesizes NO from Larginine through an oxidation process that involves transference of 5 electrons by the intermediary NGhydroxy-L-arginine. 7, 8 The substrates used by this enzyme are the amino acid L-arginine and molecular oxygen, and the cofactors required are flavine adenine mononucleotide, tetrahydrobiopterin (BH4), flavine adenine mononucleotide (FMN), and flavine adenine dinucleotide (FAD) nicotinamide adenine dinucleotide phosphate (NADPH). In addition, the last 2 isoforms contain binding sites for the heme molecule and calmodulin, both essential for its activity. After union of the calcium-calmodulin complex to eNOS (between the COOH-terminal reductase domain and the NH2-terminal oxydase domain), the electrons are yielded by the NADPH and then transported to the oxygenase domain, which contains the hem group, resulting in citrulin and NO formation 9 ( Figure 2 ). 
MOLECULAR MECHANISMS OF ENDOTHELIAL DYSFUNCTION

Reduction of NO production eNOS transcription alteration
Although the term inducible has been restricted to iNOS, the expression of eNOS is also regulated by a variety of stimuli. 10 There is extensive evidence about factors that decrease eNOS expression, including tumor necrosis factor alpha (TNF-a), which unstabilizes eNOS ARNm, apparently through regulatory proteins' increasing affinity for the 3# domain of the iNOS ARNm molecule. 11, 12 Other stimuli that have been reported as ARNm stability reducers include lipopolysaccharide, 13 hypoxia, 14 and high concentrations of oxidized lowdensity lipoprotein molecules (LDL ox ) 15 ( Figure 3 ).
Alteration in eNOS activity
Decrease in BH4 intracellular concentrations and uncoupling phenomena
Under some circumstances, eNOS can generate superoxide anion instead of NO as a consequence of a decline in BH4 concentration; this process is known as the NADPH oxidation/NO synthesis uncoupling phenomenon. 16 Superoxide radical production is mediated through the hem group in the eNOS oxygenase domain when arginine and BH4 concentrations are relatively low. [17] [18] [19] Mammals cells can generate BH4 through the enzymatic action of guanosine triphosphate (GTP) cyclohydrolase I (GTPCH I). 20 Physiological studies have shown a significant decrease in GTPCH I and BH4 activity in various pathological states such as insulin resistance, cigarette smoking, and hypercholesterolemia, probably through an LDL ox increase, as well as increased expression in some pro-inflammatory cytokines (TNF-a and interleukin-1b) [21] [22] [23] [24] ( Figure 4 ). Furthermore, clinical and experimental studies have confirmed that acute administration of BH4 improves endothelial dysfunction related to hypercholesterolemia, atherosclerosis, hypertension, and smoking. [25] [26] [27] [28] These mechanisms expose an important link between prepathogenic states involved in endothelial dysfunction development.
Competitive inhibition of eNOS by asymmetric dimethylarginine
Vallance et al 29 first described in 1992 asymmetric dimethylarginine (ADMA) as an NOS endogenous inhibitor. Since then, the role of this molecule in the FIGURE 2. eNOS biology. Nitric oxide is a key biological messenger, playing a role in a variety of biological process. Nitric oxide, formerly known as the "endothelium-derived relaxing factor" or EDRF, is biosynthesised from arginine and oxygen by various nitric oxide synthase (NOS) found in leucocytes, endothelial cells and nervous tissues. NOS are a group of enzymes (EC 1.14.13.39) responsible for the synthesis of nitric oxide (NO) from the terminal nitrogen atom of L-arginine in the presence of O2 and the cofactors nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), heme, tetrahydrobiopterin (BH4) by a five electron oxidation reaction with the production of NG-hydroxi-Larginine as intermediary reagent.
FIGURE 3.
Factors that promote eNOS expression decrease. A new facet in eNOS regulation is the important contribution of nuclear transcriptional and cytosolic posttranscriptional processes to eNOS expression. For instance, eNOS transcription rates increase in response to lysophosphatidylcholine, shear stress, and TGF-b, among others. In the other hand, atherosclerosis and proinflammatory stimuli like lipopolysacharides, oxidized low-density lipoprotein, and hypoxia, play a significant role in eNOS mRNA destabilization and a rapid downregulation in its mRNA levels.
regulation of endothelial NO synthesis has attracted increasing attention. This amino acid is synthesized in endothelial cells from arginine by an enzyme belonging to the arginine protein methyl transferase (PRMTs) family, specifically PRMT-1. 30 Earlier experimental evidence showed that supplementation with L-arginine improves endothelium-dependent vasodilatation impairment in rabbits with hypercholesterolemia and atherosclerosis, 31, 32 diminishes platelet aggregation, 33 and inhibits monocyte adhesion 34 and vascular smoothmuscle proliferation. 35 These findings are markedly in contrast with experimental studies that showed failure of L-arginine endothelium-dependent vasodilatation stimulation in isolated arterial rings and in vitro studies showing eNOS saturation at physiological L-arginine concentrations as well as failure of exogenous Larginine administration to achieve an enzyme's activity increment, confirming a lack of L-arginine vasodilator effect in isolated arterial rings. 36 This discrepancy between findings observed in intact animals versus in vitro assays was termed the ''L-arginine paradox'' and can be explained by the existence of an L-arginine competitive inhibitor now known as ADMA. Thus, administration of L-arginine at high doses should displace ADMA from the eNOS catalytic site and restore NO production to physiological levels in intact experimental models and humans. 36, 37 The expression and activity of PRMT-1 and consequently of ADMA synthesis are modulated in endothelial cells by a variety of stimuli. For example, an increase in the expression of this enzyme had been observed in response to LDL 38 molecules and shear stress, conducive to intracellular ADMA concentration. On the other hand, PRMT-1 activity can be blocked by the suppression of a group of protein kinases called kappa beta inhibitors kinase (kb-IK), which phosphorylate a group of proteins known as kappa beta inhibitors (kb-l). Once phosphorylated, these are unable to retain the kb nuclear factor (kb-NF) in the cytoplasm, which then becomes free to translocate to the nucleus site and exerts its function as a transcription factor. 38 This suggests a regulatory interplay by cytokines in the increase of its activity. In addition, multiple pathogenic factors such as hypercholesterolemia, hyperglycemia, pro-inflammatory cytokines, and hyperhomocysteinemia can diminish the activity of dimethylarginine dimethyl aminohydrolase (DDAH), an enzyme responsible for hydrolyzed ADMA degradation, causing a significant intracellular elevation of this aminoacid 38 ( Figure 5 ). Thus, the nexus between cardiovascular disease risk factors, ADMA, and endothelial dysfunction is becoming evident in conjunction with the essential role of oxidative stress in the generation of atherosclerosis.
Lipids and caveolae metabolism
Studies conducted worldwide have indicated that the location of eNOS in the cell determines its enzymatic activity. A place of particular importance in the cell for the function of this enzyme is the caveolae. 40 Caveolae are specialized invaginations in the plasmatic membrane whose main components are cholesterol, glycosphingolipids, and a structural protein called caveolin. 41 All evidence indicates that numerous extracellular stimuli exert their signal transduction through these structures. 42 In this sense, the location of eNOS in caveolae determines the inhibition of its enzymatic activity by caveolin-1 linkage, 43 which causes a blockade in eNOS interaction with the calmodulin when the intracellular calcium levels are low. 44 Also, high levels of oxidized LDLs cause a decrease in cholesterol content of caveolae, resulting in caveolin-1-eNOS complex translocation to the cytoplasm and, consequently, inhibition of its activity. 45 Likewise, there is evidence that hypercholesterolemic serum and native LDL are capable of upregulating the caveolin-1 concentration, increasing heterocomplex formation between eNOS and this protein, and diminishing NO production. 45 Furthermore, it is known that some proatherogenic lipids, such as lysophosphatidylcholine and LDL ox , interfere with FIGURE 4. eNOS uncoupling. For NO synthesis by eNOS is necessary adequate concentrations of BH4 and LArginine . When some of these sustrates and co-factors are diminishes eNOS is not able to generate NO, producing on the contrary superoxide anion, a toxic free oxygen radical. The biological toxicity of this molecule is due to its capacity to inactivate iron-sulfur cluster containing enzymes (which are critical in a wide variety of metabolic pathways), thereby liberating free iron in the cell, which can undergo Fenton reaction and generate the highly reactive hydroxyl radical.
signal transduction from receptors that activate eNOS [46] [47] [48] (acetylcholine receptors, bradykinin, serotonin, histamine, and others) ( Figure 6 ). This process enlightens other mechanisms that correlate prepathogenic and/or pathological conditions with the decrease in NO levels and therefore endothelial dysfunction.
Decrease in NO bioavailability
Increase in arginase activity
Arginase is a key enzyme involved in arginine-to-ornithine (and urea) conversion. This enzyme has two isoforms, arginase I, which is constitutively expressed in the endothelial cells, and arginase II, which can be induced by lipopolysaccharides and interferon-g. 39 Thus, systemic or local infectious processes can generate a significant increase in arginase levels, causing an important decrease in arginine and consequently a lack in eNOS substrate bioavailability and thus failure of NO synthesis.
Oxidative stress
Even in the presence of adequate NO generation, some circumstances prevent this molecule from reaching its biological targets because of a decrease in its bioavailability, as a consequence of interaction with certain chemical compounds. 49 There is abundant experimental evidence indicating the role of NO oxidative inactivation as a mediator of endothelial dysfunction and a prepathogenic vascular phenotype. 5 For example, in hyperlipidemia, excessive LDL synthesis entails a concomitant formation of LDL ox , which results in oxidative stress that causes NO conversion to peroxynitrite (a chemical species without the biological effects of NO) by a reaction that proceeds at the rate of 6.7 3 10 9 M/s
21
. 51, 52 This velocity is approximately 3 times higher than that of the reaction occurring between superoxide and superoxide dismutase (SOD). Thus, in a compartment with NO, superoxide, and SOD, the superoxide anion is able to react with either of the 2 other compounds. 5 The results of different studies support the role of the superoxide as an essential element in the decrease of NO bioavailability in oxidative stress conditions. In rabbits with aortic atherosclerosis, a remarkable decrease in endotheliumrelated relaxation was seen (despite an NO synthesis increase of up to 3 times greater than the NO synthesis level in healthy rabbits), which was corrected by SOD treatment. 53 Likewise, ascorbic acid infusion improves the vascular response to acetylcholine in smokers, diabetics, and patients with high blood pressure.
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Hyperglycemic stress
Hyperglycemia increases oxygen-derived free radical production via increased arachidonic acid metabolism. In human aortic endothelial cells, although extended exposition to high glucose concentration increases eNOS expression, a concomitant elevation in superoxide anions (probably from NADH/NADPH oxidase) results in NO inactivation. In addition, extended hyperglycemic stress causes an accumulation of advanced glycosylation end products (AGES), which are able to inactivate NO. In fact, the capacity of endotheliumdependent vessel relaxation in diabetic rats can be partially altered by administration of aminoguanidine (an AGES). [54] [55] [56] Thus, it is easy to deduce the importance of this mechanism as a remarkable connection between diabetes and cardiovascular disease.
CONCLUDING REMARKS
Endothelial dysfunction and, more specifically, alteration in NO synthesis or action constitute an essential step in the pathophysiology of most prevalent cardiovascular diseases. Because of essential NO functions (antiatherogenic, antithrombotic, antiproliferative), important changes are produced in the endothelial physiology when its biodisponibility is distorted. The multiple processes related to the reduction of synthesis and bioavailability of NO are far from being completely clarified. Although a significant and growing body of information has been acquired, studies devoted to comprehension of the biology of eNOS and its pathological modifications in the course of endothelial dysfunction are still needed. These will allow generation of new pharmacological strategies for early treatment of coronary heart disease and, consequently, prevention of the most-feared complications by safe and efficient means.
